Femasys holds promotional launch of FemCerv

Femasys reported that it held a promotional launch of its diagnostic product, FemCerv, the first endocervical tissue sampler designed to improve tissue quality and quantity at the annual meeting of AAGL, where the product was very well received by gynecologic physicians and surgeons. The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures. "During our recent market launch and presentation of FemCerv at AAGL, a major medical meeting of gynecologic surgeons and other related specialists, we were extremely encouraged by the interest expressed related to the product," said Kathy Lee-Sepsick, CEO. "Gynecologic specialists acknowledged the novelty of FemCerv, an endocervical curette that obtains a virtually pain free comprehensive tissue sample when evaluating for cervical cancer. The current process relies on antiquated tools that can be painful and result in an inadequate or contaminated sample, which may lead to unnecessary invasive procedures. We were also extremely pleased to hear positive feedback from gynecologic specialists about FemVue, our first of its kind commercially available diagnostic product for infertility that enables ultrasound evaluation of the fallopian tubes. FemVue works in conjunction with our other approved product, FemCath, a selective catheter, which is expected to be commercially available later this month. By the end of this year, we will offer three commercially available products in our portfolio in addition to our leading clinical development programs, FemaSeed and FemBloc. Our goal is to elevate care and expand options for women with our suite of innovative products like FemVue, FemCerv, and FemCath that may provide meaningful additional incremental revenue in the near-term, while we complete the clinical development programs for FemaSeed and FemBloc."